Search

Your search keyword '"Pedersini, R"' showing total 18 results
Start Over Author "Pedersini, R" Database Academic Search Index
18 results on '"Pedersini, R"'

1. 1693P Accurate triage may be efficacious in selecting patients who could safely continue anticancer therapy during SARS-CoV-2 pandemic.

Author

Gurizzan, C., Pedersini, R., Fornaro, C., Sardini, C., Zamparini, M., Monteverdi, S., Tovazzi, V., Cosentini, D., Dalla Volta, A., Baggi, A., Turla, A., Di Mauro, P., Lorini, L., Laganà, M., Bianchi, S., Intagliata, S., Consoli, F., Conti, E., Bossi, P., and Berruti, A.

Subjects
*COVID-19 pandemic, *MEDICAL triage
Published
2020
Full Text
View/download PDF

3. The Burden of Rheumatoid Arthritis in Russia.

Author

Pedersini, R, Karateev, DE, Vasilescu, RS, Alvir, JM, Spurden, D, Smolen, JS, Karateev, D E, Vasilescu, R S, Alvir, J M, and Smolen, J S

Subjects
*RHEUMATOID arthritis treatment, *RUSSIANS, *MEDICAL centers, *MEDICAL care costs, *MEDICAL research, *DISEASES
Published
2015
Full Text
View/download PDF

13. Correlations between family history and cancer characteristics in 2256 breast cancer patients.

Author

Molino, A., Giovannini, M., Pedersini, R., Frisinghelli, M., Micciolo, R., Mandara, M., Pavarana, M., Cetto, G. L., and Mandarà, M

Subjects
*GENEALOGY, *BREAST cancer patients, *ESTROGEN receptors, *CANCER invasiveness, *TUMORS, *CANCER in women, *PROTEIN analysis, *RESEARCH, *RESEARCH methodology, *CASE-control method, *EVALUATION research, *TUMOR classification, *COMPARATIVE studies, *DISEASE susceptibility, *AGE factors in disease, *BREAST tumors
Abstract

A comparison of 692 early invasive breast cancer with, and 1564 without, a family history of breast cancer showed that the former were younger at diagnosis (P=0.002), had smaller tumours (P=0.012), were more frequently oestrogen receptor positive (P=0.006) and diagnosed preclinically (P<0.001). [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

14. Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence.

Author

Zambelli, A., Gallerani, E., Garrone, O., Pedersini, R., Rota Caremoli, E., Sagrada, P., Sala, E., and Cazzaniga, ME

Subjects
*HORMONE receptor positive breast cancer, *EPIDERMAL growth factor receptors, *HORMONE receptors, *TUMOR classification, *BREAST cancer
Abstract

Hormone-receptor positive (HR+), Human-Epidermal-growth Factor negative (HER2-) breast cancer, including the Luminal A and the Luminal B subtypes, is the most common in women diagnosed with early-stage BC. Despite the advances in screening, surgery and therapies, recurrence still occurs. Therefore, it is important to identify early those factors that significantly impact the recurrence risk. Based on current evidence and their professional expertise, a Panel of oncologists discussed the definition of high risk of recurrence in early breast cancer. Histological grade, nodal involvement, genomic score, histological grade, tumor size, and Ki-67 proliferation index were rated as the most important factors to define the high risk in patients with early breast cancer. All these factors should be considered comprehensively to tailor the choice of treatment to the peculiar characteristics of each patient. [Display omitted] • Recurrence still occurs in early HR+ HER2- breast cancer. • Determination of recurrence risk is required to optimize the therapeutic approach. • Histological grade and nodal involvement are the most important factors. • Genomic score, Ki-67, and tumor size are also relevant to define the risk. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. 227P Peripheral blood lymphocyte counts predict clinical outcomes in patients with hormone receptor-positive HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.

Author

Vernieri, C., Zattarin, E., Mariani, L., Menichetti, A., Leporati, R., Ligorio, F., Fuca, G., Lobefaro, R., Griguolo, G., Sirico, M., Bernocchi, O., Marra, A., Agostinetto, E., Jacobs, F., di Mauro, P., Curigliano, G., Pedersini, R., Losurdo, A., Generali, D., and Dieci, M.V.

Subjects
*METASTATIC breast cancer, *CYCLIN-dependent kinase inhibitors, *LYMPHOCYTE count, *TREATMENT effectiveness, *HORMONES
Published
2022
Full Text
View/download PDF

17. 339P Impact of blood glucose levels on the efficacy of everolimus-exemestane in patients with advanced HR-positive/HER2 negative breast cancer: The EVERMET study.

Author

Vernieri, C., Nichetti, F., Guarneri, V., Cortesi, E., Moscetti, L., Del Mastro, L., Fabbri, A., Curigliano, G., Montemurro, F., Losurdo, A., Generali, D.G., Fabi, A., Pedersini, R., Ciccarese, M., Rocca, A., Arpino, G., La Verde, N.M., Puglisi, F., Mariani, L., and de Braud, F.

Subjects
*BREAST cancer, *BLOOD sugar
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results